تقرير
أعرض في EDS

Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy.

التفاصيل البيبلوغرافية
العنوان: Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy.
المؤلفون: Jain V; Department of Neurology, University of Florida College of Medicine, Gainesville, USA., Remley W; Department of Neurology, Lake Erie College of Osteopathic Medicine, Jacksonville, USA., Bunag C; Department of Neurology, University of Florida College of Medicine, Gainesville, USA., Elfasi A; Department of Neurology, University of Florida, Gainesville, USA., Chuquilin M; Department of Neurology, University of Florida, Gainesville, USA.
المصدر: Cureus [Cureus] 2022 May 19; Vol. 14 (5), pp. e25129. Date of Electronic Publication: 2022 May 19 (Print Publication: 2022).
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Checkpoint inhibitor immunotherapies have been one of the latest advances through the last decade in the treatment of various cancers. As their use is increasing so is the knowledge of their complications which can affect various organ systems including the central and peripheral nervous systems. Management of these complications requires stopping the offending agent and in some cases treating with immunosuppressive agents like intravenous steroids. Physicians can face challenging situations if patients are unresponsive to steroids, intravenous immunoglobulins (IVIG), and plasmapheresis (PLEX). There are no formal guidelines to help in the management of such patients.  We present an 85-year-old male with a past medical history of renal cell carcinoma status post nephrectomy who was admitted with diplopia, eyelid ptosis, dysphagia, dysphonia, dyspnea, and generalized weakness. He was started on nivolumab and ipilimumab 10 days prior to presentation. Laboratory studies showed an elevated erythrocyte sedimentation rate, C-reactive protein, and creatine phosphokinase, and an unrevealing lumbar puncture. Acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies were negative. Electromyography and nerve conduction studies showed axonal and demyelinating sensorimotor neuropathy with no significant decrement on 3 Hz repetitive stimulation. Thyroid function tests were concerning for thyroiditis and anti-thyroid peroxidase antibodies were positive. Together, these findings led to the diagnosis of refractory myositis and acute neuropathy along with autoimmune thyroiditis from nivolumab and ipilimumab immunotherapy. His symptoms were unresponsive to a 5-day course of steroids, intravenous immunoglobulins, and plasmapheresis. He was then started on rituximab with significant improvement in ptosis, dysphagia, dysphonia, and proximal weakness. Immune checkpoint inhibitors (ICI) are associated with an increased risk for the development of various autoimmune conditions. Treatment involves discontinuation of the offending drug and initiation of immunosuppressive therapy. This case is interesting as it demonstrates the importance of the awareness of the neurological complications of the checkpoint inhibitor therapies and the beneficial role of rituximab in patients who are unresponsive to initial immunosuppressive therapies including steroids, IVIG, and PLEX.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2022, Jain et al.)
References: J Immunother Cancer. 2019 May 22;7(1):134. (PMID: 31118078)
Eur J Cancer. 2017 Mar;73:1-8. (PMID: 28064139)
Ann Oncol. 2021 Feb;32(2):282-283. (PMID: 33309745)
Front Pharmacol. 2017 Feb 08;8:49. (PMID: 28228726)
Cureus. 2021 Jul 12;13(7):e16337. (PMID: 34395120)
Nature. 2011 Mar 31;471(7340):561. (PMID: 21455150)
JAMA Oncol. 2018 Feb 01;4(2):173-182. (PMID: 28973656)
J Clin Oncol. 2012 Feb 20;30(6):e76-8. (PMID: 22203769)
Ann Oncol. 2017 Feb 1;28(2):377-385. (PMID: 28426103)
Nervenarzt. 2019 Feb;90(2):138-147. (PMID: 30073487)
Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704)
فهرسة مساهمة: Keywords: check point therapy complication; myositis from checkpoint inhibitor therapy; neuropathy from checkpoint inhibitor therapy; refractory neurological complication from check point therapy; rituximab in myasthenia from ipilimumab
تواريخ الأحداث: Date Created: 20220623 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9206120
DOI: 10.7759/cureus.25129
PMID: 35733495
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.25129